Jeremy Bender

Stories

Servier spends $2.5 billion on Day One Biopharmaceuticals to lock in a rare pediatric cancer treatment

As of May 2026: Leading Day One through Servier acquisition

For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the FDA cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Day One Biopharmaceuticals, the company behind it, has agreed to be acquired by France's Servier for $2.5 billion in cash—a 68% premium over its previous closing share price.

Updated May 30

Notable Quotes

"Servier's successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One's mission to bring medicines to patients of all ages with life-threatening diseases." — Statement on Servier acquisition, March 2026

from Servier spends $2.5 billion on Day One Biopharmaceuticals to lock in a rare pediatric cancer treatment · Updated May 30